Bone marrow lesions in the knee: early results of patients treated with subcondroplasty by Randelli, Pietro et al.
Introduction
Bone marrow lesions (BMLs) of the knee are 
common subchondral bone defects that can be 
found in some fluid-sensitive MRI’s sequences 
[T2/proton density with fat suppression and short 
tau inversion recovery (STIR)] as an hyperintensity 
area or an edema-like signal (black arrow) [1]. 
The clinical and radiological meaning of these 
lesions is still controversial, but BMLs are often 
correlated with pain and functional impairment of 
the knee. This kind of alterations on MRI can be a 
sign of different pathological meanings like bone 
oedema but also trabecular necrosis, bone cysts, 
fibrosis and, moreover, they are an indirect sign 
of the presence of cartilaginous fragments. The 
etiopathogenesis of bone marrow lesions involves 
an alteration of the subchondral bone characterized 
by oedema but also fibrosis, leukocyte infiltration, 
increase in vascularity associated with medullary 
necrosis, bone microfractures and a mineralization 
deficit: all these processes bring to an anomalous 
bone remodelling [2,3,4].
Bone marrow lesions of the knee can be divided 
in two main groups: traumatic and atraumatic. The 
differential diagnosis includes several conditions: 
contusions or traumatic fractures, cysts and 
erosions, developmental chondrosis, immobility 
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and overload, transitory bone oedema syndrome, 
subchondral insufficiency fractures of the knee 
(SIFK) and osteonecrosis [5;6]. 
Traumatic BMLs tend to resolve spontaneously 
within 2-4 months and include: lesions associated 
with major traumas, bone contusions, subacute 
lesions related to overload and sport related 
repetitive microtraumatism. The most common 
example of bone contusions is observed in ACL 
tears: a bone edema can be seen on the lateral 
femoral condyle about the sulcus and in the 
posterior and lateral area of the tibial plateau [7]. 
In overextension injuries, bone contusions are 
located on anterior portion of proximal tibia and 
distal femur: they can be an indirect sign of PCL 
lesions. BMLs are also common in people affected 
by early or severe osteoarthritis [8,9] and they can 
be associated with meniscal tears or insufficiency 
and focal cartilage defects [10;14;15].
Other pathologies which cause BMLs include 
reversible and irreversible conditions. Among the 
reversible ones we count Transient osteoporosis 
(TOP), Regional migratory osteoporosis (RMO) 
and Complex regional pain syndrome (CRPS), 
also called Reflex sympathetic dystrophy (RSD) 
or Algodistrophy. All these conditions present 
a similar radiological pattern: diffuse hyper-
intensity signal in the subchondral bone with 
blurred edges, that involves the articular surface 
without damaging it. The differential diagnosis 
between these conditions is based on age, sex 
and patient’s clinical history. On the other hand, 
we have irreversible conditions like Spontaneous 
osteonecrosis of the knee (SONK), avascular 
necrosis and post-arthroscopic or cartilage surgery 
osteonecrosis; among them we can include also 
Subchondral insufficiency fractures (SIFK) 
that can become irreversible if the subchondral 
fragment undergoes true necrosis and a low T1WI 
signal >4 mm thick is visible on MRI [8;9]. 
Subchondroplasty
Bone marrow lesions natural course involves 
persistence of knee pain and functional impairment 
and eventually partial or total/unicompartmental 
knee replacement in some years from the diagnosis. 
The treatment options include a conservative or a 
surgical approach, depending on the size of the 
lesion and the presence of a necrotic area. Lesions 
larger than 5 cm² can lead to a subchondral bone 
collapse, so they often require an arthroplasty 
implantation. Conversely, lesions sized between 
3.5 and 5 cm² can regress and even smaller lesions 
often heal spontaneously, therefore a conservative 
approach is indicated in lesions smaller than 3.5 
cm² that don’t present necrosis. That includes 
NSAIDs, analgesic drugs, controlled load for 
3-8 months. Other specific strategies available 
are pulsed electromagnetic fields (PEMFs), 
prostacyclin and bisphosphonates. For example, 
Iloprost, a prostacyclin analogous, promotes a 
better tissue perfusion, especially in the bone, it 
can also reduce pain and favor the regress of bone 
edema in small lesions, but the pharmacological 
effects at the base of these phenomena are not 
clear yet. Bisphosphonates, such as Ibadronate and 
Neridronate, can inhibit osteoclasts and reduce 
bone resorption. Clinical results after their use in 
the treatment of BML are not clear: many studies 
Figure 1 - A typical case of bone marrow lesion in 
femoral condyle
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show clinical and radiological improvements 
when used in osteonecrosis, transient bone marrow 
lesion syndrome and in CRPS [7,10-12;17]; 
instead, other studies show no difference between 
ibadronate and placebo [18]. In case of failure of 
these therapeutic options, a knee arthroplasty was 
often performed.
Recently, a new surgical procedure has been 
introduced into the clinical practice with the aim of 
reducing pain, avoiding or at least delaying a knee 
replacement: subchondroplasty. Subchondroplasty 
is a percutaneous procedure in which calcium 
phosphate, a biocompatible material very similar 
to the native bone apatite with osteo-inductive 
properties, is injected inside BML areas [19]. 
The goals of subchondroplasty are relieving 
patient’s symptoms, improving the mechanical 
strenght of subchondral bone, stimulating bone 
remodelling to avoid bone sagging and slowing 
down the arthritic degenerative process in order 
to postpone arthroplasty. The indications for this 
procedure include: knee pain for at least 3 months, 
evidence of a bone marrow lesion on MRI, failure 
of conservative treatment, presence of located 
pain in the oedema area. On the other hand, the 
main contraindications are: pain and functional 
limitation due to other diseases, ligamentous 
laxity, varus/valgus axial deviation greater than 8 
degrees, severe osteoarthritis.
The surgical procedure is based on an accurate pre-
operative planning: it is very important to measure 
the lesion size on MRI and calculate its distance to 
the cortical bone on all the planes. Patient is placed 
supine with the affected limb elevated compared 
to the contralateral to allow a better view on intra-
operative x-rays. The bone substitute is prepared 
mixing calcium phosphate granules with 3 cc of 
saline solution until a homogeneous material 
is obtained. Under fluoroscopic guidance, led 
by the pre-operative planning, 5 cc of calcium 
phosphate solution is then injected through a 
fenestrate cannula. The procedure is followed by 
an arthroscopic joint debridement in order to treat 
concomitant pathologies and eventually remove 
intra-articular calcium phosphate leakage.
Subchondroplasty has few complications 
represented by a leakage inside or outside knee 
joint during injection and failure of the procedure 
which can be due to inadequate indications such as 
diffuse osteoarthritis, an error during the surgical 
procedure or the presence of concomitant defects, 
not visible on MRI. Treatment in case of failure, 
which includes the persistence of knee pain and 
progression of arthritis, involves a total or partial 
Figure 2 - Pre-operative planning and some images of surgical procedure
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knee replacement [20;21;22;23].
Material and methods
The main aim of the present cohort study is 
evaluating the effects of subchondroplasty 
associated to knee arthroscopy in reducing pain and 
improving in knee function in patients suffering 
from bone marrow lesions associated to mild or 
moderate osteoarthritis. The clinical outcome has 
been assessed at 1, 6 and 12 months follow-up. 
Secondarily, edema healing and bone remodelling 
of the affected areas have been checked at every 
follow-up by x-ray and MRI.
The inclusion criteria are: presence of atraumatic 
knee pain and functional impairment for at least 
3 months; failure of conservative treatment 
(including NSAIDs, physical therapy, intra-
articular injection with steroids or hyaluronic 
acid and bisphosphonates); presence of a mild to 
moderate osteoarthritis (Kellgren-Lawrence grade 
< 3); presence of BML on a loading area at MRI 
imaging (femoral condyles and/or tibial plateau); 
presence of localized pain in the BML area; written 
informed consent to be included into the study. 
Exclusion criteria comprehend: knee pain and 
functional limitation related to other causes 
like osteonecrosis, fractures and inflammatory 
arthritis; the presence of a ligamentous instability; 
malalignment on the coronal axis greater than 10 
degrees in varus/valgus; severe tri-compartmental 
arthritis (Kellgren-Lawrence grade 4). 
Every patient included has been evaluated pre-
operatively and then at each follow-up clinically 
and by MRI. Four validated orthopaedics scores 
have been used to assess patients’ symptoms and 
knee function: Numeric pain Rating Scale (NRS) 
[24]; Knee Society Score (KSS) [25]; Western 
Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) [26]; International Knee 
Documentation Committee (IKDC) [27].
Subchondroplasty procedure has been performed 
following the previously described technique 
and followed by an arthroscopic assessment of 
the intra articular structures’ conditions and the 
ensure the lack of any calcium phosphate leakage. 
A final check by x-ray has been performed and the 
patient could be discharged the day after surgery. 
Progressive weight bearing with two crutches has 
been allowed from the first day after the operation 
and a gradual recovery of complete ROM has been 
encouraged. 
Follow-up (months)
Score  0 1 6 12 P value (0-6) 
months
n. pz 9 3 5 3
NRS  8.00 [8.00 – 9.00] 3.00 [1.00 – 8.00] 1.00 [1.00 – 3.00] 2.00 [1.00 – 2.00] 0.0625
n. pz 9 2 5 2
IKDC 15.11 (± 7.70) 50.00 [44.80 – 55.20] 63.20 [50.30 – 71.25] 53.45 [39.10 – 67.80] 0.0625
n. pz 9 1 5 2
WOMAC 62.39 (± 15.33) 15.00 [15.00 – 15.00] 7.00 [3.50 – 23.00] 17.50 [7.00 – 28.00] 0.0625
n. pz 9 3 5 2
KSS objective 69.67 (± 3.35) 88.00 [80.00 – 90.00] 89.00 [82.50 – 92.50] 89.50 [86.00 – 93.00] 0.0625
n. pz 9 3 5 2
KSS satisfaction 5.11 (± 5.21) 32.00 [32.00 – 35.00] 31.00 [28.50 – 35.00] 31.00 [30.00 – 32.00] 0.0625
n. pz 9 3 5 2
KSS expectation 9.22 (± 2.39) 15.00 [9.00 – 15.00] 12.00 [9.00 – 14.00] 12.00 [12.00 – 12.00] 0.25
n. pz 9 3 5 2
KSS functionality 18.89 (± 6.77) 49.00 [45.00 – 67.00] 59.00 [46.50 – 72.00] 51.00 [40.00 – 62.00] 0.0625
Table 1 - Complete follow-up of patients treated with subcondroplasty
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Statistical analysis of the collected data was 
performed as follows: every clinical score 
obtained at each follow-up has been compared to 
pre-op values through a paired t-test and Wilcoxon 
matched-pairs signed rank test for paired and not-
paired data according with the normality of the 
data. Values lower than 0.05 (p<0.05) have been 
considered statistically significant.
Data and results
Data collection started in April 2017 and it is still 
in progress. Following the inclusion criteria, up 
to now we have enrolled 9 patients. Demographic 
characteristics of our patients are reported in table 
1.
 The mean age of the patients included in the study 
was about 70 years old, with women predominance 
(7 females and 2 males). The average Body Mass 
Index was 27 kg/m². All the bone marrow lesions 
treated were situated in the medial compartment: 
5 patients on the medial femoral condyle, 2 on the 
medial tibial plateau and 2 patients had a combined 
lesion. 
The preliminary collected data showed an 
improvement in every score at 6 months after 
surgery compared to the baseline. In particular, 
NRS scale changed from a mean value of 8 to 1, 
revealing a marked improvement of pain after the 
procedure, even though not statistically significant 
(p-value 0.0625). Furthermore, IKDC and 
WOMAC scores showed an improvement in knee 
function 6 months after Subchondroplasty, from 
15.11 to 63.20 and from 62.39 to 7.00 respectively 
(p-value 0.0625); KSS in every section (objective, 
satisfaction and function) raised as well during the 
follow-up, though without statistical significance.
Conclusions
The main finding of our study is a satisfying pain 
reduction and a good functional improvement 
reported after subchondroplasty procedure 
associated with arthroscopic debridement. NRS 
scale showed a marked reduction of symptoms 
already in an early phase after the procedure and 
a further progressive improvement through the 
follow-up. Pain reduction seems also durable 
according to the low value registered at 12 months 
of follow-up. WOMAC and IKDC indicated 
a severe impairment in knee function before 
the treatment, while after subchondroplasty 
procedure, a remarkable increase of the average 
values associated with the performance of daily 
activities and joint related symptoms was found. 
Mean Objective KSS before surgery was about 
70, quite elevated because of the strict inclusion 
criteria which indicate Subchondroplasty only in 
the absence of joint instability and severe varus/
valgus deviations; anyway, the score was not 
influenced by the procedure. Regarding Subjective 
KSS, which investigates knee pain during some 
activities like walking and climbing stairs, we 
recorded a little positive variation that can suggest 
an initial improvement still requiring a longer time 
to reach an excellent outcome. KSS “expectation” 
evaluation, the most subjective part of the score 
and influenced by some external factors, revealed 
not statistically significant results (p = 0.25). 
Results at 6 months follow-up present a p value 
of 0.0625, therefore they are not statistically 
significant, probably due to the small sample 
size, but still the collected data are promising for 
a satisfying clinical outcome after this procedure. 
Only two patients reached 12 months follow-up so 
their analysed scores are not representative of the 
clinical trend of all our patients.
This study presents several limitations. First of 
all, the lack of a control group does not allow a 
direct analysis of the effects of subchondroplasty 
procedure. Another limitation is the absence of 
standardization in the data collection during the 
follow-up; the study is still ongoing and only few 
patients have reached 12 months of follow-up, so 
our data are still incomplete. Furthermore, during 
the arthroscopic time after subchondroplasty, 
a partial meniscectomy was performed in two 
patients and in one case a high tibial osteotomy 
was added as a treatment for early osteoarthritis. 
These procedures can have influenced the results 
and brought benefits to the patient independently 
from the investigated treatment.
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However, our preliminary findings are similar 
to the ones reported in literature and show that 
subchondroplasty is a mini-invasive procedure 
that has good results at short term in the treatment 
of BML associated with early and moderate 
osteoarthritis. This procedure can also be considered 
a safe surgery since we reported only few minor 
complications. Our patients had remarkable 
benefit from the procedure and they were satisfied 
with their outcome. Only one failure was recorded: 
one patient reported severe pain at 1-month follow-
up and after only 3 months from the procedure a 
total knee arthroplasty was implanted. The failure 
reason is not clear yet but it could be associated 
with a severe grade of arthritis. This case allowed 
to verify that the calcium phosphate injection 
does not influence a following joint replacement 
procedure since no complications occurred during 
and after the implantation.
In conclusion, we can confirm that subchondroplasty 
is a safe, reliable and effective procedure for the 
treatment of bone marrow lesions associated with 
moderate grade of arthritis. The effects at long term 
still have to be verified. Further studies and more 
data are necessary to prove the real efficacy and 
durability of this emerging technique and to better 
define the inclusion and exclusion criteria in order 
to better address the patients who could benefit the 
most from this promising treatment.
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